All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
EMA grants gilteritinib regulatory review for the treatment of patients with relapsed/refractory FLT3-positive acute myeloid leukemia
Bookmark this article
On 1 March 2019, the European Medicines Agency (EMA) accepted a marketing authorization application and granted regulatory review to gilteritinib, a potent, oral fms-like tyrosine kinase 3 (FLT3) inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) FLT3-positive acute myeloid leukemia (AML).1 This comes after gilteritinib received FDA approval for the treatment of patients with FLT3-positive R/R AML in November 2018.
The marketing authorization application is based on the results from the randomized phase III ADMIRAL study (NCT02421939), which is assessing the efficacy of oral gilteritinib vs salvage chemotherapy in adult patients with FLT3-positive R/R AML. Interim results from the trial demonstrated a complete remission/complete remission with partial hematologic recovery rate of 21%.2 The results from the ADMIRAL trial are to be presented at the American Association for Cancer Research Annual Meeting 2019, Atlanta, USA, in March 2019.
According to the drug manufacturers, the marketing authorization application for gilteritinib to the EMA received accelerated assessment, which could result in a shorter timeframe for approval from the Committee for Medicinal Products for Human Use.
- Pharmafield. EMA accepts marketing authorization application for XOSPATA (gilteritinib). https://pharmafield.co.uk/pharma_news/ema-accepts-maa-for-xospatatm-gilteritinib/ [Accessed 2019 Mar 04]
- Perl A.E. et al. An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. J Clin Oncol. 35, 2017 (suppl; abstr #TPS7067). 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, 2017 June 2–6; Chicago, IL, USA.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox